PLAT and Stroke: In 1995, the National Institute of Neurological Disorders and Stroke (NINDS) stroke trial confirmed the benefit of intravenous tissue plasminogen activator (tPA) in improving three-month outcomes, including a higher proportion of patients with a modified Rankin Scale score of 0–1 (functional independence without disability) when administered within 3 h of ischaemic stroke symptom onset [14].